- Home
- Equipment
- usa massachusetts
- lung cancer
Show results for
Refine by
Lung Cancer Equipment Supplied In Usa Massachusetts
14 equipment items found
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas. ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous non-small cell lung ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. UpRi is being studied in UPLIFT, a single-arm ...
Manufactured by:NeuroLogica Corporation based inDanvers, MASSACHUSETTS (USA)
Aiming to bring life-saving low-dose lung screenings to under-served areas of the United States, NeuroLogica has partnered with Winnebago to provide access to mobile computed tomography (CT) clinics across America. According to the American Lung Association, approximately eight million people in the U.S. are at high risk for lung ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled tumor progression and growth.4 Similar to Kristen rat sarcoma (KRAS), p53 mutations ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of cancer, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer. ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the Wilms’ Tumor 1 (WT1) antigen, an over-expressed protein that is often associated with AML and other cancers. We have nominated NTLA-5001 as our initial development candidate for AML and expect to enter the clinic in 2021. ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
AV-203 (CAN017) is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
An autologous mHsp70 targeted NK Cell Therapy that activates NK cells to target and kill cells expressing mHsp70. The therapy begins with selecting patients whom have high mHsp70 expression with our Companion Diagnostic AP-CDx (described below), collecting their peripheral blood mononuclear cells (PBMCs) by leukapheresis, ex vivo activation of PBMCs with our synthetic Hsp70-derived peptide ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Dubermatinib (TP-0903) is an investigational inhibitor of AXL receptor tyrosine kinase (RTK), a protein known to be involved in acquiring resistance to chemotherapeutics, immune evasion, and developing metastatic capacity in cancer ...
Manufactured by:Cellanyx, LLC based inBeverly, MASSACHUSETTS (USA)
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no metastatic potential. There are two sub types – Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The incidence of these entities is ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK cells are expanded, and incubated ex vivo with TKD and IL-2, followed by freezing, thawing and intravenous administration to ...
Manufactured by:Fujifilm Healthcare Americas Corporation based inLexington, MASSACHUSETTS (USA)
SCENARIA View 128 is a powerful premium performance CT solution that provides dependable routine application capabilities with available advanced clinical modules for Interventional CT, extended coverage Shuttle Scanning (for Perfusion Exams), Cardiac CTA and Dual Energy examinations. The View employs 64 discrete detector and electronics channels over a 40mm detector coverage and reconstructs up ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell response, including both CD4+ and CD8+ ...